Lupus & antiphospholipid syndrome
Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis
Authors' conclusion
This meta-analysis emphasised the meaningful correlation between MPA AUC and C0 with renal response in LN treatment.
Study context
- Population
- Patients with lupus nephritis (LN) receiving mycophenolic acid (MPA) treatment; studies reporting both MPA pharmacokinetic parameters and renal outcomes
- Participants
- 433 patients16 studies
- Comparison
- Responders vs non-responders: MPA pharmacokinetics
- Outcome
- Relationship between clinical (renal) response and MPA pharmacokinetics
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
As reported in the abstract
MPA-AUC, responders vs non-responders
Further pooled results
Mean, mg/L
| Outcome | Response | Non-response | Weighted mean difference (mg/L) (95% CI) | P value | |
|---|---|---|---|---|---|
| MPA trough concentration (C0) | 2.50 (SD 1.73) | 1.51 (SD 1.33) | 1.37 (0.77–1.97) | P < 0.001 | |
| −1012Difference, mg/L (linear scale) |
Safety
- No significant relationship identified between MPA-AUC and adverse events
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis. Lupus Sci Med. Published 17 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →